We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
Read MoreHide Full Article
IDEXX Laboratories, Inc. (IDXX - Free Report) , a leading manufacturer of products and services primarily for the companion animal veterinary, has rallied 9.1% over the last six months, beating the S&P 500’s 5.3% gain. The stock has a market cap of $13.55 billion. The company’s five-year historical growth rate is also favorable at 19.8% as compared with 18% of the broader industry.
Also, the company represented a return of almost 9.1%, better than the broader industry’s gain of 8.2% over the last year.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at the moment.
The company’s estimate revision trend for the current year has also been positive. In the past 60 days, five analysts moved north, with no movement in the opposite direction. The magnitude of estimate revision for earnings rose around 3.9% to $3.17 per share over the same time frame.
Let’s find out whether the recent positive trend is a sustainable one. Recently, IDEXX ended the second quarter of 2017 on a solid note, with earnings and revenues beating the Zacks Consensus Estimate.
The stellar quarterly performance was driven by the company’s companion animal business. The companion animal market fundamentals remain solid with tremendous global runway for growth. Management’s unique innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerated recurring CAG Diagnostics revenue growth. Moreover, the strong top-line growth in this quarter was driven by considerable contributions from the rest of the business segments.
Also, IDEXX recently announced the addition of rVetLink to its portfolio of technology applications. Notably, rVetLink is an advanced all-inclusive referral management solution designed for specialty care hospitals that simplifies the referral procedure between primary care and specialty care veterinarians.
This apart, IDEXX continues to display solid growth with respect to international expansion. The company has been significantly benefitting from the companion animal market of emerging nations, demonstrating the bountiful opportunities.
Additionally, the company has a strong cash balance that enables it to carry out share repurchase programs and in turn provide solid returns to investors.
On the flip side, foreign currency fluctuation is a major headwind for the company. Another concern is the company’s high reliance on third-party distributors. The purchasing dynamics of distributors have a significant impact on the company’s sales of instrument consumables and rapid assay products. Also, the company faces higher operating expenses pertaining to increased head count along with higher investments targeted toward growth acceleration in geographical expansion in the United States and internationally, and portfolio expansion. Moreover, the competitive landscape in the domestic and overseas markets weighs on IDEXX’s performance.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 28.8% over the last six months.
Steris has a positive earnings surprise of 0.78% for two of the trailing four quarters. The stock has gained 26.3% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 66.1% over the last six months.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Image: Bigstock
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
IDEXX Laboratories, Inc. (IDXX - Free Report) , a leading manufacturer of products and services primarily for the companion animal veterinary, has rallied 9.1% over the last six months, beating the S&P 500’s 5.3% gain. The stock has a market cap of $13.55 billion. The company’s five-year historical growth rate is also favorable at 19.8% as compared with 18% of the broader industry.
Also, the company represented a return of almost 9.1%, better than the broader industry’s gain of 8.2% over the last year.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at the moment.
The company’s estimate revision trend for the current year has also been positive. In the past 60 days, five analysts moved north, with no movement in the opposite direction. The magnitude of estimate revision for earnings rose around 3.9% to $3.17 per share over the same time frame.
Let’s find out whether the recent positive trend is a sustainable one. Recently, IDEXX ended the second quarter of 2017 on a solid note, with earnings and revenues beating the Zacks Consensus Estimate.
The stellar quarterly performance was driven by the company’s companion animal business. The companion animal market fundamentals remain solid with tremendous global runway for growth. Management’s unique innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerated recurring CAG Diagnostics revenue growth. Moreover, the strong top-line growth in this quarter was driven by considerable contributions from the rest of the business segments.
Also, IDEXX recently announced the addition of rVetLink to its portfolio of technology applications. Notably, rVetLink is an advanced all-inclusive referral management solution designed for specialty care hospitals that simplifies the referral procedure between primary care and specialty care veterinarians.
This apart, IDEXX continues to display solid growth with respect to international expansion. The company has been significantly benefitting from the companion animal market of emerging nations, demonstrating the bountiful opportunities.
Additionally, the company has a strong cash balance that enables it to carry out share repurchase programs and in turn provide solid returns to investors.
On the flip side, foreign currency fluctuation is a major headwind for the company. Another concern is the company’s high reliance on third-party distributors. The purchasing dynamics of distributors have a significant impact on the company’s sales of instrument consumables and rapid assay products. Also, the company faces higher operating expenses pertaining to increased head count along with higher investments targeted toward growth acceleration in geographical expansion in the United States and internationally, and portfolio expansion. Moreover, the competitive landscape in the domestic and overseas markets weighs on IDEXX’s performance.
Other Key Picks
Other top-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , Steris Plc (STE - Free Report) and Lantheus Holdings, Inc.(LNTH - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Steris and Lantheus Holdings carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 28.8% over the last six months.
Steris has a positive earnings surprise of 0.78% for two of the trailing four quarters. The stock has gained 26.3% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 66.1% over the last six months.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>